⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromoethane SCHEMBL1330309 | 1.00 | — | — | |
| Bromoethane SCHEMBL2322 | 1.00 | — | — | |
| Bromoethane SCHEMBL1331842 | 1.00 | — | — | |
| Bromoethane SCHEMBL8586792 | 0.93 | — | — | |
| Bromoethane SCHEMBL7932013 | 0.93 | — | — | |
| Bromoethane SCHEMBL23628450 | 0.93 | — | — | |
| Bromoethane SCHEMBL349037 | 0.93 | — | — | |
| Bromoethane SCHEMBL5032176 | 0.93 | — | — | |
| Bromoethane SCHEMBL7896802 | 0.93 | — | — | |
| Bromoethane SCHEMBL1097947 | 0.93 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110256418-B | 1, 3-thiazol-2-yl substituted benzamides | 拜耳公司 | 2023-01-20 | — | — | CN | disclosed |
| CN-113395993-A | Heterocyclic compounds and their use | 武田药品工业株式会社 | 2021-09-14 | — | — | CN | disclosed |
| CN-108026050-B | Novel compounds as ROR gamma modulators | 格兰马克药品股份有限公司 | 2021-04-30 | — | — | CN | disclosed |
| CN-107207507-B | 1, 3-thiazol-2-yl substituted benzamides | 拜耳公司 | 2020-11-06 | — | — | CN | disclosed |
| EP-3609869-A1 | SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | Bayer Aktiengesellschaft (DE) | 2020-02-19 | — | — | EP | disclosed |
| CN-110730776-A | Substituted N-arylethyl-2-arylquinoline-4-carboxamides and their use | 拜耳股份公司 | 2020-01-24 | — | — | CN | disclosed |
| EP-3519389-A1 | NOVEL 5-SUBSTITUTED IMIDAZOLYLMETHYL DERIVATIVES | Bayer CropScience Aktiengesellschaft (DE) | 2019-08-07 | — | — | EP | disclosed |
| WO-2018098209-A1 | AMINO SULFONYL COMPOUNDS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2018-05-31 | — | — | WO | disclosed |
| WO-2018060091-A1 | NOVEL 5-SUBSTITUTED IMIDAZOLYLMETHYL DERIVATIVES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2018-04-05 | — | — | WO | disclosed |
| US-9428523-B2 | 2-amino-6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,3-thiazol-4-yl amides | PFIZER INC. (US) | 2016-08-30 | — | — | US | disclosed |
| WO-2006128175-A2 | POLYMERS, COMPOSITIONS AND METHODS OF MAKING THE SAME | UNIVERSITY OF MASSACHUSETTS (US) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006048236-A1 | PROCESS FOR THE PREPARATION OF ALKYL 5- (DICARBOXIMIDO) LEVULINATE AND ALKYL 4-OXO-PENTENOATE | BIOSYNTH AB (SE) | 2006-05-11 | — | — | WO | disclosed |
| US-6825354-B2 | OSTEOPOROSIS; RHEUMATIC DISEASES | WYETH HOLDINGS CORPORATION | 2004-11-30 | — | — | US | disclosed |
| EP-1147080-B1 | ALKYNYL CONTAINING HYDROXAMIC ACID COMPOUNDS AS TACE INHIBITORS | WYETH CORP (US) | 2004-07-21 | — | — | EP | disclosed |
| US-20020147342-A1 | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors | AMERICAN CYANAMID COMPANY (US) | 2002-10-10 | — | — | US | disclosed |
| US-6340691-B1 | TREATMENT OF ARTHRITIS, TUMOR METASTASIS, TISSUE ULCERATION, ABNORMAL WOUND HEALING, PERIODONTAL DISEASE, BONE DISEASE, DIABETES (INSULIN RESISTANCE) AND HIV INFECTION | AMERICAN CYANAMID COMPANY | 2002-01-22 | — | — | US | disclosed |
| EP-1149843-A1 | SUBSTITUTED PHENETHYLAMINE DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-10-31 | — | — | EP | disclosed |
| EP-1147080-A1 | ALKYNYL CONTAINING HYDROXAMIC ACID COMPOUNDS AS TACE INHIBITORS | American Cyanamid Company (US) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000044713-A1 | ALKYNYL CONTAINING HYDROXAMIC ACID COMPOUNDS AS TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
| EP-0099121-A2 | Pharmaceutical compositions | Bristol-Myers Company (US) | 1984-01-25 | — | — | EP | disclosed |